Celularity (CELU) Total Current Liabilities (2018 - 2025)
Celularity's (CELU) quarterly Total Current Liabilities came in at $80.8 million in Q4 2025, up 50.45% year-over-year from $53.7 million in Q4 2024, and up 23.65% quarter-over-quarter from $65.3 million in Q3 2025.
Analysis
Celularity (CELU) Total Current Liabilities (2018 - 2025) Analysis & Trends
Celularity (CELU) has reported Total Current Liabilities for 8 consecutive years, with $80.8 million the latest figure, recorded in Q4 2025.
- On a quarterly basis, Total Current Liabilities rose 50.45% year-over-year to $80.8 million in Q4 2025; TTM through Dec 2025 was $80.8 million, a 50.45% increase from a year earlier, with the FY2025 full-year figure at $80.8 million, up 50.45% from the prior year.
- Total Current Liabilities was $80.8 million for Q4 2025 at Celularity, up from $65.3 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $84.6 million in Q3 2023 and troughed at $5.2 million in Q1 2021.
- A 5-year average of $54.0 million and a median of $65.1 million in 2023 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities surged 20571.7% in 2021 and decreased 20.24% in 2024, its largest moves.
- Over 5 years, Total Current Liabilities stood at $26.2 million in 2021, then surged by 136.75% to $62.1 million in 2022, then grew by 8.39% to $67.3 million in 2023, then declined by 20.24% to $53.7 million in 2024, then jumped by 50.45% to $80.8 million in 2025.
- The last three Total Current Liabilities figures came in at $80.8 million (Q4 2025), $65.3 million (Q3 2025), and $69.2 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | 127.40 Mn |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | 132.90 Mn |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | 106.85 Mn |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | 403.60 Mn |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 83.35 Mn |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | 80.88 Mn |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 29.35 Mn |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | 502.91 Mn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 52.53 Mn |
| 10 | Celularity | 36.35 Mn | 30.17 Mn | -3.27 Mn | 80.76 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 80.76 Mn |
| Sep 30, 2025 | 65.31 Mn |
| Jun 30, 2025 | 69.23 Mn |
| Mar 31, 2025 | 58.69 Mn |
| Dec 31, 2024 | 53.68 Mn |
| Sep 30, 2024 | 76.17 Mn |
| Jun 30, 2024 | 67.90 Mn |
| Mar 31, 2024 | 66.04 Mn |
| Dec 31, 2023 | 67.30 Mn |
| Sep 30, 2023 | 84.63 Mn |
| Jun 30, 2023 | 64.98 Mn |
| Mar 31, 2023 | 66.46 Mn |
| Dec 31, 2022 | 62.09 Mn |
| Sep 30, 2022 | 69.22 Mn |
| Jun 30, 2022 | 32.94 Mn |
| Mar 31, 2022 | 26.03 Mn |
| Dec 31, 2021 | 26.23 Mn |
| Sep 30, 2021 | 29.21 Mn |
| Jun 30, 2021 | 7.29 Mn |
| Mar 31, 2021 | 5.16 Mn |